Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + sintilimab + anlotinib
- Development stage
- Unknown
- Lead developer
- Sun Yat-Sen Memorial Hospital
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
liposomal irinotecan + sintilimab + anlotinib is a combination therapy regimen being evaluated for the treatment of recurrent or persistent ovarian clear cell carcinoma (OCCC). The regimen consists of liposomal irinotecan, a nanoparticle-encapsulated topoisomerase I inhibitor that induces DNA damage in cancer cells; sintilimab, a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor to restore anti-tumor immune responses; and anlotinib, an oral multi-target tyrosine kinase inhibitor that suppresses tumor angiogenesis and growth by inhibiting VEGFR, FGFR, PDGFR, and c-Kit. This triplet combination is currently being studied in a Phase II clinical trial (NCT06143371) sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University to assess its efficacy and safety in patients with OCCC, a subtype of ovarian cancer known for its poor prognosis and resistance to standard platinum-based chemotherapy.
- Brand names
- OnivydeTyvytFukanghua
- Other names
- Liposomal irinotecan, sintilimab, and anlotinib combinationIrinotecan liposome injection + sintilimab + anlotinib
02
Targets
VEGFR4 (Vascular endothelial growth factor Receptor-3)FGFR3 (Fibroblast growth factor receptor 3)TOP1 (DNA Topoisomerase I)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on liposomal irinotecan + sintilimab + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + sintilimab + anlotinib.